Skip to main content
Erschienen in: Nuclear Medicine and Molecular Imaging 3/2016

11.04.2016 | Original Article

The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

verfasst von: Hansol Moon, Woo Chul Noh, Hyun-Ah Kim, Eun-Kyu Kim, Ko Woon Park, Seung Sook Lee, Joon Ho Choi, Kyung Woo Han, Byung Hyun Byun, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Sang Moo Lim

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study investigates the correlation of retention index (RI) using the dual phase FDG PET/CT scan with the breast cancer biomarkers.

Methods

A total of 55 patients with breast cancer underwent dual phase FDG PET/CT scans (60 and 120 min after FDG injection) before treatment. SUVmax and SUVmean of the primary breast tumors were measured, then the percent change of SUVmax and SUVmean between the two scans were calculated, and denoted as RImax and RImean, respectively. After the surgical resection of the breast tumor, the status of biomarkers (ER, PR, and HER-2) was evaluated in the postsurgical specimen.

Results

RImean was significantly higher in ER (−) (median, 16.2; IQR, 10.8–21.0) or HER-2 (+) (median, 16.1; IQR, 10.7–21.6) tumors than in ER (+) tumors (median, 9.9; IQR, 5.5–15.3) or HER-2 (−) tumors (median, 10.5; IQR, 5.5–16.1). However, there were no significant differences of SUVmax or RImax according to the ER or HER-2 status. There were no significant differences of any PET parameters between PR (+) and PR (−) tumors. Based off ROC curve analyses, RImean predicted the ER (+) tumors (AUC, 0.699; p = 0.006), and HER-2 (+) tumors (AUC, 0.674; p = 0.022), but not the PR (+) tumors. However, neither SUVmax nor RImax predicted ER (+), PR (+), or HER-2 (+) tumors.

Conclusions

Retention index of SUVmean can reflect the ER and HER-2 status of breast cancers. Higher retention index of SUVmean might associate with lower ER expression and higher HER-2 expression.
Literatur
1.
Zurück zum Zitat Jung KW, Won YJ, Kong HJ, Oh CM, et al. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013;45(1):1–14.CrossRefPubMedPubMedCentral Jung KW, Won YJ, Kong HJ, Oh CM, et al. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013;45(1):1–14.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Ahn SH. Korean Breast Cancer S. Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg. 2004;139(1):27–30. discussion 31.CrossRefPubMed Ahn SH. Korean Breast Cancer S. Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg. 2004;139(1):27–30. discussion 31.CrossRefPubMed
3.
Zurück zum Zitat Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2(3):133–40.CrossRefPubMed Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2(3):133–40.CrossRefPubMed
4.
Zurück zum Zitat Sariego J, Zrada S, Byrd M, Matsumoto T. Breast cancer in young patients. Am J Surg. 1995;170(3):243–5.CrossRefPubMed Sariego J, Zrada S, Byrd M, Matsumoto T. Breast cancer in young patients. Am J Surg. 1995;170(3):243–5.CrossRefPubMed
5.
Zurück zum Zitat Harris L, Fritsche H, Mennel R, Norton L, et al. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312.CrossRefPubMed Harris L, Fritsche H, Mennel R, Norton L, et al. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312.CrossRefPubMed
6.
Zurück zum Zitat Groheux D, Giacchetti S, Rubello D, Al-Nahhas A, et al. The evolving role of PET/CT in breast cancer. Nucl Med Commun. 2010;31(4):271–3.CrossRefPubMed Groheux D, Giacchetti S, Rubello D, Al-Nahhas A, et al. The evolving role of PET/CT in breast cancer. Nucl Med Commun. 2010;31(4):271–3.CrossRefPubMed
7.
Zurück zum Zitat Danforth Jr DN, Aloj L, Carrasquillo JA, Bacharach SL, et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat. 2002;75(2):135–46.CrossRefPubMed Danforth Jr DN, Aloj L, Carrasquillo JA, Bacharach SL, et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat. 2002;75(2):135–46.CrossRefPubMed
8.
Zurück zum Zitat Groheux D, Moretti JL, Baillet G, Espie M, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008;71(3):695–704.CrossRefPubMed Groheux D, Moretti JL, Baillet G, Espie M, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008;71(3):695–704.CrossRefPubMed
9.
Zurück zum Zitat Fuster D, Duch J, Paredes P, Velasco M, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26(29):4746–51.CrossRefPubMed Fuster D, Duch J, Paredes P, Velasco M, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26(29):4746–51.CrossRefPubMed
10.
Zurück zum Zitat Schwarz-Dose J, Untch M, Tiling R, Sassen S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27(4):535–41.CrossRefPubMed Schwarz-Dose J, Untch M, Tiling R, Sassen S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27(4):535–41.CrossRefPubMed
11.
Zurück zum Zitat Couturier O, Jerusalem G, N’Guyen JM, Hustinx R. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006;12(21):6437–43.CrossRefPubMed Couturier O, Jerusalem G, N’Guyen JM, Hustinx R. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006;12(21):6437–43.CrossRefPubMed
12.
Zurück zum Zitat Baba S, Isoda T, Maruoka Y, Kitamura Y, et al. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. J Nucl Med. 2014;55(5):736–42.CrossRefPubMed Baba S, Isoda T, Maruoka Y, Kitamura Y, et al. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. J Nucl Med. 2014;55(5):736–42.CrossRefPubMed
13.
Zurück zum Zitat Riedl CC, Slobod E, Jochelson M, Morrow M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014;55(10):1578–83.CrossRefPubMedPubMedCentral Riedl CC, Slobod E, Jochelson M, Morrow M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014;55(10):1578–83.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36(10):1766–74.PubMed Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36(10):1766–74.PubMed
15.
Zurück zum Zitat Crippa F, Seregni E, Agresti R, Chiesa C, et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 1998;25(10):1429–34.CrossRefPubMed Crippa F, Seregni E, Agresti R, Chiesa C, et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med. 1998;25(10):1429–34.CrossRefPubMed
16.
Zurück zum Zitat Avril N, Menzel M, Dose J, Schelling M, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42(1):9–16.PubMed Avril N, Menzel M, Dose J, Schelling M, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42(1):9–16.PubMed
17.
Zurück zum Zitat Buck A, Schirrmeister H, Kuhn T, Shen C, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29(10):1317–23.CrossRefPubMed Buck A, Schirrmeister H, Kuhn T, Shen C, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29(10):1317–23.CrossRefPubMed
18.
Zurück zum Zitat Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20(2):379–87.CrossRefPubMed Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20(2):379–87.CrossRefPubMed
19.
Zurück zum Zitat Kumar R, Chauhan A, Zhuang H, Chandra P, et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 2006;98(3):267–74.CrossRefPubMed Kumar R, Chauhan A, Zhuang H, Chandra P, et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat. 2006;98(3):267–74.CrossRefPubMed
20.
Zurück zum Zitat Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, et al. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96(2):166–70.CrossRefPubMed Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, et al. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96(2):166–70.CrossRefPubMed
21.
Zurück zum Zitat Garcia Vicente AM, Castrejon AS, Relea Calatayud F, Munoz AP, et al. 18F-FDG retention index and biologic prognostic parameters in breast cancer. Clin Nucl Med. 2012;37(5):460–6.CrossRefPubMed Garcia Vicente AM, Castrejon AS, Relea Calatayud F, Munoz AP, et al. 18F-FDG retention index and biologic prognostic parameters in breast cancer. Clin Nucl Med. 2012;37(5):460–6.CrossRefPubMed
22.
Zurück zum Zitat Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E. Dual time point FDG-PET/CT imaging… Potential tool for diagnosis of breast cancer. Clin Radiol. 2008;63(11):1213–27.CrossRefPubMed Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E. Dual time point FDG-PET/CT imaging… Potential tool for diagnosis of breast cancer. Clin Radiol. 2008;63(11):1213–27.CrossRefPubMed
23.
Zurück zum Zitat Mavi A, Urhan M, Yu JQ, Zhuang H, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47(9):1440–6.PubMed Mavi A, Urhan M, Yu JQ, Zhuang H, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47(9):1440–6.PubMed
24.
Zurück zum Zitat Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42(9):1412–7.PubMed Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42(9):1412–7.PubMed
25.
Zurück zum Zitat Houseni M, Chamroonrat W, Zhuang J, Gopal R, et al. Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med. 2010;51(4):535–42.CrossRefPubMed Houseni M, Chamroonrat W, Zhuang J, Gopal R, et al. Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med. 2010;51(4):535–42.CrossRefPubMed
26.
Zurück zum Zitat Chen HH, Lee BF, Su WC, Lai YH, et al. The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2013;40(10):1478–85.CrossRefPubMed Chen HH, Lee BF, Su WC, Lai YH, et al. The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2013;40(10):1478–85.CrossRefPubMed
27.
Zurück zum Zitat Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, et al. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2005;32(4):389–97.CrossRefPubMed Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, et al. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2005;32(4):389–97.CrossRefPubMed
28.
Zurück zum Zitat Xi Y, Guo R, Hu J, Zhang M, et al. 18F-fluoro-2-deoxy-D-glucose retention index as a prognostic parameter in patients with pancreatic cancer. Nucl Med Commun. 2014;35(11):1112–8.CrossRefPubMed Xi Y, Guo R, Hu J, Zhang M, et al. 18F-fluoro-2-deoxy-D-glucose retention index as a prognostic parameter in patients with pancreatic cancer. Nucl Med Commun. 2014;35(11):1112–8.CrossRefPubMed
29.
Zurück zum Zitat Sanghera B, Wong WL, Lodge MA, Hain S, et al. Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun. 2005;26(10):861–7.CrossRefPubMed Sanghera B, Wong WL, Lodge MA, Hain S, et al. Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun. 2005;26(10):861–7.CrossRefPubMed
30.
Zurück zum Zitat Abgral R, Le Roux PY, Rousset J, Querellou S, et al. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma. Nucl Med Commun. 2013;34(6):551–6.CrossRefPubMed Abgral R, Le Roux PY, Rousset J, Querellou S, et al. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma. Nucl Med Commun. 2013;34(6):551–6.CrossRefPubMed
31.
Zurück zum Zitat Cheang MC, Chia SK, Voduc D, Gao D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50.CrossRefPubMedPubMedCentral Cheang MC, Chia SK, Voduc D, Gao D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Shimoda W, Hayashi M, Murakami K, Oyama T, et al. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14(3):260–8.CrossRefPubMed Shimoda W, Hayashi M, Murakami K, Oyama T, et al. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14(3):260–8.CrossRefPubMed
33.
Zurück zum Zitat Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012;53(7):1041–7.CrossRefPubMedPubMedCentral Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012;53(7):1041–7.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Lindstrom LS, Karlsson E, Wilking UM, Johansson U, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21):2601–8.CrossRefPubMed Lindstrom LS, Karlsson E, Wilking UM, Johansson U, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21):2601–8.CrossRefPubMed
35.
Zurück zum Zitat Slamon DJ, Clark GM, Wong SG, Levin WJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.CrossRefPubMed Slamon DJ, Clark GM, Wong SG, Levin WJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.CrossRefPubMed
36.
Zurück zum Zitat Higashi T, Saga T, Nakamoto Y, Ishimori T, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43(2):173–80.PubMed Higashi T, Saga T, Nakamoto Y, Ishimori T, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43(2):173–80.PubMed
37.
Zurück zum Zitat Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J. 2004;377(Pt 2):347–55.CrossRefPubMedPubMedCentral Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J. 2004;377(Pt 2):347–55.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006;25(34):4777–86.CrossRefPubMedPubMedCentral Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006;25(34):4777–86.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Groheux D, Giacchetti S, Moretti JL, Porcher R, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426–35.CrossRefPubMed Groheux D, Giacchetti S, Moretti JL, Porcher R, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426–35.CrossRefPubMed
40.
Zurück zum Zitat Heudel P, Cimarelli S, Montella A, Bouteille C, et al. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010;15(6):588–93.CrossRefPubMed Heudel P, Cimarelli S, Montella A, Bouteille C, et al. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010;15(6):588–93.CrossRefPubMed
41.
Zurück zum Zitat Mavi A, Cermik TF, Urhan M, Puskulcu H, et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007;48(8):1266–72.CrossRefPubMed Mavi A, Cermik TF, Urhan M, Puskulcu H, et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007;48(8):1266–72.CrossRefPubMed
42.
Zurück zum Zitat Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, et al. Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. Nucl Med Commun. 2013;34(11):1055–67.CrossRefPubMed Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, et al. Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. Nucl Med Commun. 2013;34(11):1055–67.CrossRefPubMed
43.
Zurück zum Zitat Borst GR, Belderbos JS, Boellaard R, Comans EF, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41(11):1533–41.CrossRefPubMed Borst GR, Belderbos JS, Boellaard R, Comans EF, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41(11):1533–41.CrossRefPubMed
44.
Zurück zum Zitat Lee JR, Madsen MT, Bushnel D, Menda Y. A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun. 2000;21(7):685–90.CrossRefPubMed Lee JR, Madsen MT, Bushnel D, Menda Y. A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun. 2000;21(7):685–90.CrossRefPubMed
45.
Zurück zum Zitat Lim I, Noh WC, Park J, Park JA, et al. The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(10):1852–60.CrossRefPubMed Lim I, Noh WC, Park J, Park JA, et al. The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(10):1852–60.CrossRefPubMed
46.
Zurück zum Zitat Basu S, Chen W, Tchou J, Mavi A, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112(5):995–1000.CrossRefPubMed Basu S, Chen W, Tchou J, Mavi A, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112(5):995–1000.CrossRefPubMed
47.
Zurück zum Zitat Chen YM, Huang G, Sun XG, Liu JJ, et al. Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan. Nucl Med Commun. 2008;29(5):425–30.CrossRefPubMed Chen YM, Huang G, Sun XG, Liu JJ, et al. Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan. Nucl Med Commun. 2008;29(5):425–30.CrossRefPubMed
48.
Zurück zum Zitat Chen CJ, Lee BF, Yao WJ, Cheng L, et al. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol. 2008;191(2):475–9.CrossRefPubMed Chen CJ, Lee BF, Yao WJ, Cheng L, et al. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol. 2008;191(2):475–9.CrossRefPubMed
49.
Zurück zum Zitat Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E, et al. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT. Eur J Radiol. 2009;70(3):530–8.CrossRefPubMed Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E, et al. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT. Eur J Radiol. 2009;70(3):530–8.CrossRefPubMed
50.
Zurück zum Zitat Boerner AR, Weckesser M, Herzog H, Schmitz T, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med. 1999;26(3):226–30.CrossRefPubMed Boerner AR, Weckesser M, Herzog H, Schmitz T, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med. 1999;26(3):226–30.CrossRefPubMed
51.
Zurück zum Zitat Hamberg LM, Hunter GJ, Alpert NM, Choi NC, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35(8):1308–12.PubMed Hamberg LM, Hunter GJ, Alpert NM, Choi NC, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35(8):1308–12.PubMed
52.
Zurück zum Zitat Kumar R, Loving VA, Chauhan A, Zhuang H, et al. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med. 2005;46(11):1819–24.PubMed Kumar R, Loving VA, Chauhan A, Zhuang H, et al. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med. 2005;46(11):1819–24.PubMed
53.
Zurück zum Zitat Lowe VJ, Duhaylongsod FG, Patz EF, Delong DM, et al. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology. 1997;202(2):435–9.CrossRefPubMed Lowe VJ, Duhaylongsod FG, Patz EF, Delong DM, et al. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology. 1997;202(2):435–9.CrossRefPubMed
55.
Zurück zum Zitat Perou CM, Sorlie T, Eisen MB, van de Rijn M, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.CrossRefPubMed Perou CM, Sorlie T, Eisen MB, van de Rijn M, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.CrossRefPubMed
56.
Zurück zum Zitat Sorlie T, Perou CM, Tibshirani R, Aas T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.CrossRefPubMedPubMedCentral Sorlie T, Perou CM, Tibshirani R, Aas T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Chung CH, Bernard PS, Perou CM. Molecular portraits and the family tree of cancer. Nat Genet. 2002;32(Suppl):533–40.CrossRefPubMed Chung CH, Bernard PS, Perou CM. Molecular portraits and the family tree of cancer. Nat Genet. 2002;32(Suppl):533–40.CrossRefPubMed
58.
Zurück zum Zitat Sorlie T, Tibshirani R, Parker J, Hastie T, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23.CrossRefPubMedPubMedCentral Sorlie T, Tibshirani R, Parker J, Hastie T, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23.CrossRefPubMedPubMedCentral
59.
Zurück zum Zitat Goldhirsch A, Wood WC, Coates AS, Gelber RD, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–47.CrossRefPubMedPubMedCentral Goldhirsch A, Wood WC, Coates AS, Gelber RD, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–47.CrossRefPubMedPubMedCentral
Metadaten
Titel
The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT
verfasst von
Hansol Moon
Woo Chul Noh
Hyun-Ah Kim
Eun-Kyu Kim
Ko Woon Park
Seung Sook Lee
Joon Ho Choi
Kyung Woo Han
Byung Hyun Byun
Ilhan Lim
Byung Il Kim
Chang Woon Choi
Sang Moo Lim
Publikationsdatum
11.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 3/2016
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-016-0412-2

Weitere Artikel der Ausgabe 3/2016

Nuclear Medicine and Molecular Imaging 3/2016 Zur Ausgabe